Patisiran in hereditary transthyretin-mediated amyloidosis-Reference-Cited by-同舟云学术

Patisiran in hereditary transthyretin-mediated amyloidosis

Published:2021-01 Issue:1 Volume:20 Page:21-23
ISSN:1474-4422
Container-title:The Lancet Neurology
language:en
Short-container-title:The Lancet Neurology

Author:

Luigetti Marco,Servidei Serenella

Publisher

Elsevier BV

Subject

Clinical Neurology

Reference10 articles.

1. Diagnosis and treatment of hereditary transthyretin amyloidosis (hATTR) polyneuropathy: current perspectives on improving patient care;Luigetti;Ther Clin Risk Manag,2020

2. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy;Coelho;J Neurol,2013

3. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis;Adams;N Engl J Med,2018

4. Inotersen treatment for patients with hereditary transthyretin amyloidosis;Benson;N Engl J Med,2018

5. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study;Adams;Lancet Neurol,2020

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Selection of GalNAc-Conjugated siKeap1 as Disease-Specific Delivery System for Chemotherapy-Induced Liver Injury and Chronic Liver Disease;Nano Letters;2024-01-22

2. Genetic counseling and related issues;Neurogenetics for the Practitioner;2024

3. Protein-based delivery systems for RNA delivery;Journal of Controlled Release;2023-11

4. Progress on RNA-based therapeutics for genetic diseases;Journal of Zhejiang University (Medical Sciences);2023-08-01

5. Development of Cationic Lipid LAH4-L1 siRNA Complexes for Focused Ultrasound Enhanced Tumor Uptake;Molecular Pharmaceutics;2023-03-29